We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy (DM200-101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00638716
Recruitment Status : Completed
First Posted : March 19, 2008
Results First Posted : June 2, 2017
Last Update Posted : June 2, 2017
Sponsor:
Information provided by (Responsible Party):

March 13, 2008
March 19, 2008
May 2, 2017
June 2, 2017
June 2, 2017
February 2008
November 2008   (Final data collection date for primary outcome measure)
Reduction of HbA1c From Baseline [ Time Frame: Screening and Day 85 ]
Change from Baseline
HbA1c [ Time Frame: Screening, and Days 1, 15, 36, 57, 78, 85, and 106 ]
Complete list of historical versions of study NCT00638716 on ClinicalTrials.gov Archive Site
  • Reduction in FPG From Baseline [ Time Frame: Screening and Day 85 ]
    Change from Baseline
  • Reduction in Fasting Body Weight From Baseline [ Time Frame: Screening and Day 85 ]
    Change from Baseline
Incidence, duration, and intensity of Adverse Events [ Time Frame: Continuously ]
Not Provided
Not Provided
 
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus Who Are Currently on Metformin Monotherapy
A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Phase II Study to Evaluate the Efficacy and Safety of 3 Months of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study.

The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients with type 2 diabetes mellitus who are currently on metformin monotherapy.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: CJC-1134-PC
    1.5 or 2.0 mg CJC-1134-PC
  • Drug: Placebo
    Placebo
  • Experimental: 1
    12 weekly doses of 1.5 mg CJC-1134-PC
    Intervention: Drug: CJC-1134-PC
  • Experimental: 2
    4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
    Intervention: Drug: CJC-1134-PC
  • Placebo Comparator: 3
    12 weekly doses of placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
122
November 2008
November 2008   (Final data collection date for primary outcome measure)

Major Inclusion Criteria:

  • BMI: 27 to 45 kg/m2
  • Stable Type 2 diabetes mellitus for at least 3 months, as defined by the Investigator
  • Stable life-style, i.e. diet & physical activity, as determined by the Investigator
  • Stable metformin daily dose ≥1000 mg for at least 3 months
  • Glycosylated hemoglobin (HbA1c) at screening ≥ 7.1% and ≤ 11%
Sexes Eligible for Study: All
25 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00638716
DM200-101
Yes
Not Provided
Not Provided
ConjuChem
ConjuChem
Not Provided
Not Provided
ConjuChem
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP